Phase 1 CD5.CAR/28zeta CAR-T: engineered T cells targeting CD5 in T-cell malignancies

This trial investigates the safety and persistence of autologous or allogeneic CD5.CAR/28zeta T cells in patients with relapsed or refractory T-cell non-Hodgkin lymphoma and acute lymphocytic leukemia. Conducted by Baylor College of Medicine in Houston, the study evaluates a novel approach that combines CD5-targeting with CD28 co-stimulation to enhance T cell expansion and longevity.